Cargando…
The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
BACKGROUND: Ocrelizumab is approved for the treatment of both relapsing and progressive multiple sclerosis (MS). OBJECTIVE: To examine the impact of ocrelizumab on health-related quality of life (HRQOL) in individuals with MS. METHODS: Ninety-eight individuals with relapsing and 32 with progressive...
Autores principales: | Glanz, Bonnie I, Zurawski, Jonathan, Casady, Emily C, Shamah, Rebecca, Weiner, Mira, Chitnis, Tanuja, Weiner, Howard L, Healy, Brian C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138295/ https://www.ncbi.nlm.nih.gov/pubmed/34046184 http://dx.doi.org/10.1177/20552173211007523 |
Ejemplares similares
-
Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023) -
Risk attitudes and risk perceptions in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2016) -
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021) -
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021) -
History of fatigue in multiple sclerosis is associated with grey matter atrophy
por: Palotai, Miklos, et al.
Publicado: (2019)